Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
4
×
life sciences
national blog main
national top stories
new york blog main
san diego blog main
san francisco blog main
biotech
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego top stories
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
bluebird bio
clinical trials
fda
gene therapy
medicare
regeneron pharmaceuticals
vertex pharmaceuticals
alex azar
alirocumab
alnylam pharmaceuticals
ambys medicines
american patients first
amicus therapeutics
What
drug
4
×
long
4
×
prices
awaited
details
drugs
house
lower
plan
afternoon
ago
anathema
anticipated
aren’t
bio
biotechs
blueprint
considering
cost
cut
data
democrat
developers
diseases
dyne
early
elements
expected
experimental
eyes
fda
gene
genetic
having
help
humans
imminent
ipo
ipos
leaked
Language
unset
Current search:
long
×
drug
×
" boston top stories "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details
